¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Observation for suspected toxic effect from ingested substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • latitude effect
    À§µµÈ¿°ú
  • masking effect
    ÀºÆóÈ¿°ú
  • mass effect
    µ¢ÀÌÈ¿°ú, Á¾±«È¿°ú
  • mesomeric effect
    °ø¸íÈ¿°ú
  • magnetic field effect
    ÀÚÀåÈ¿°ú
  • no-observed-effect level
    ¹«°üÂûÈ¿°ú¼öÁØ
  • on-off effect
    °³½ÃÁ¾·áÈ¿°ú
  • osmolality effect
    ¸ô¶ö»ïÅõ¾ÐÈ¿°ú
  • overkill effect
    °úÀ×Ä¡»çÈ¿°ú
  • phase shift effect
    À§»óº¯À§È¿°ú
  • photochemical effect
    ±¤È­ÇÐÈ¿°ú
  • photoconductive effect
    ±¤ÀüµµÈ¿°ú
  • photoelectric effect
    ±¤ÀüÈ¿°ú
  • photovoltaic effect
    ±¤±âÀü·ÂÈ¿°ú
  • piezoelectric effect
    ¾ÐÀüÈ¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • heparinoid substance
    ÇìÆÄ¸°¼º¹°Áú
  • heterogeneous substance
    ºÒ±ÕÁúü
  • horny substance
    °¢Áú
  • inducer substance
    À¯µµ¹°Áú
  • inhibitor substance
    ¾ïÁ¦¹°Áú
  • intercellular substance
    ¼¼Æ÷»çÀ̹°Áú
  • intercellular cement substance
    ¼¼Æ÷»çÀ̰áÇÕ¹°Áú
  • interference substance
    °£¼·¹°Áú
  • ketogenic substance
    ÄÉÅæÃ¼Çü¼º¹°Áú
  • melanophore expanding substance
    Èæ»ö¼¼Æ÷È®Àå¹°Áú
  • metachromatic substance
    ÀÌ¿°»ö¹°Áú
  • neuroactive substance
    ½Å°æÈ°¼º¹°Áú
  • neurosecretory substance
    ½Å°æºÐºñ¹°
  • odoriferous substance
    Çâ·á
  • osteoid substance
    Dz»À¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • anticurare effect
    Ç×Å¥¶ó·¹ÀÛ¿ë.
  • antioxidant effect
    Ç×»êÈ­È¿°ú(¡­üùÍý).
  • antitoxemic effect
    Ç×µ¶Ç÷ÁõÈ¿°ú.
  • antitussive effect
    ÁøÇØÈ¿°ú(òåú¦üùÍý).
  • glucose effect
    Æ÷µµ´çÈ¿°ú
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • green house effect
    ¿Â½ÇÈ¿°ú
  • halo effect
    ´Þ¹«¸® È¿°ú
  • hearing, binaural (effect)
    ¾çÀÌû(È¿°ú)
  • heat effect
    ¿­È¿°ú
  • heel effect
    µÚÃàÈ¿°ú, µÚ²Þġȿ°ú
  • hepatic first pass effect
    °£ÃÊȸÅë°úÈ¿°ú.
  • hereditary effect
    À¯ÀüÀû¿µÇâ
  • immediate effect
    Áï(°¢)È¿(°ú), Áï½ÃÈ¿°ú.
  • in-flow effect
    À¯ÀÔ È¿°ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • toxic necrosis
    Áßµ¶¼º±«»ç(¡­ÎÕÞÝ)
  • toxic nephropathy
    Áßµ¶¼º ½Åº´Áõ
  • toxic nephrosclerosis
    Áßµ¶¼º½Å°æÈ­Áõ(¡­ãìÌãûùñø)
  • toxic nephrosis
    Áßµ¶¼º½ÅÁõ(¡­ãìñø)
  • toxic neuritis
    Áßµ¶¼º½Å°æ¿°(¡­ãêÌèæú).
  • toxic neuritis
    Áßµ¶¼º½Å°æ¿°(¡­ãêÌèæú)
  • toxic psychosis
    µ¶¼ºÁ¤½ÅÁõ(~ïñãêñø).
  • toxic reaction
    µ¶¹ÝÀÀ(Ô¸Úãëë), Áßµ¶¹ÝÀÀ(ñéÔ¸Úãëë).
  • toxic retinopathy
    Áßµ¶¸Á¸·º´Áõ
  • toxic shock syndrome
    µ¶¼Ò¼ï ÁõÈıº (Æ÷µµ±¸±Õ)
  • toxic shock syndrome
    µ¶¼º ¼ïÁõÈıº
  • toxic shock syndrome toxin-1
    µ¶¼Ò¼ï ÁõÈıº À¯¹ßµ¶¼Ò-1
  • toxic tolerance
    µ¶¹°³»¼º(Ô¸ÚªÒ±àõ).
  • toxic unit
    Áßµ¶´ÜÀ§(ñéÔ¸Ó¤êÈ), µ¶¼Ò´ÜÀ§(Ô¸áÈÓ¤êÈ).
  • accelerans substance
    ÃËÁø¹°Áú(õµòäÚªòõ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • wall effect
    º®(Ûú)È¿°ú(üùÍý)
  • Warbug effect
    ¹Ù¸£ºÎ¸£Å© È¿°ú(üùÍý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
LAE   1) Late Asthmatic Effect
  2) Left Atrial Enlargement
SE Side Effect
AE above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers...
AEF allogenic effect factor; amyloid enhancing factor; aorto-enteric fistula
CE California encephalitis; cardiac enlargement; cardioesophageal; carotid endarterectomy; catamenial e...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
DLIS Digoxin-like immunoreactive substance
EDLS Endogenous digitalis-like substance
HSS Hepatic Stimulatory Substance
I-SP Immunoreactive substance P
ir SP Immunoreactive substance P
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • focus effect
    ÃÐÁ¡ È¿°ú
  • harmful effect
    À§ÇØ ÀÛ¿ë
    À§ÇèÇÑ ÀçÇØ. Á¶Á÷À̳ª »ý¸íü¿¡ ÇØ·Î¿î ¿µÇâÀ» ³¢Ä¡´Â ÀÛ¿ë.
  • heel effect
    Èú È¿°ú
    ¾ç±Ø °æ»ç °¢µµ¿¡ µû¸¥ È¿°ú.
  • indirect effect
    °£Á¢ È¿°ú
  • isotopic effect
    µ¿À§ ¿ø¼Ò È¿°ú
  • lethal effect
    Ä¡»ç È¿°ú
  • longitudinal effect
    Á¾ È¿°ú, Á¾Àû È¿°ú
  • misregistration effect
    ¿Àµî·Ï È¿°ú
  • modulating effect
    Á¶Àý È¿°ú
  • muscle effect
    ±ÙÀ° È¿°ú
  • myocardium,aging effect
    ³ëÈ­ Çö»ó
  • Nagler effect
    ³ª±Û·¯ È¿°ú
  • nonallergic side effect
    ºñ¾Ë·¹¸£±â¼º ºÎÀÛ¿ë
  • oral effect of medication
    Åõ¾àÀÇ ±¸°­³» È¿°ú
  • overkill effect
    °úÀ× Ä¡»ç È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
specific capsular substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
spongy substance Bone in which the spicules or trabeculae form a three-dimensional latticework (cancellus) with the interstices filled with embryonal connective tissue or bone marrow.
Synonym: substantia trabecularis, cancellous bone, spongy bone, spongy substance, trabecular bone.
(05 Mar 2000)
standard substance A pure, authentic substance used for identification purposes.
(05 Mar 2000)
Stilling's gelatinous substance The central gray matter of the spinal cord surrounding the central canal.
Synonym: substantia intermedia centralis et lateralis, anterior gray column, Stilling's gelatinous substance, substantia gelatinosa centralis.
(05 Mar 2000)
neurosecretory substance The secretion of nerve cell bodies located in the hypothalamus; the substance is transported by way of hypothalamo-hypophysial tract fibres into the neurohypophysis where the terminals of the nerve fibres contain the secretion. As seen in the fibres and terminals with a light microscope, the substance appears as Herring bodies or hyaline bodies of the pituitary (see under body).
See: hyaline bodies of pituitary.
(05 Mar 2000)
Nissl substance The material consisting of granular endoplasmic reticulum and ribosomes that occurs in nerve cell bodies and dendrites.
Synonym: basophil substance, basophilic substance, chromophil substance, Nissl bodies, Nissl granules, substantia basophilia, tigroid bodies, tigroid substance.
(05 Mar 2000)
substance The material constituting an organ or body, also called substantia.
Origin: L. Substantia
(18 Nov 1997)
substance abuse Maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems.
(05 Mar 2000)
substance abuse detection Detection of drugs that have been abused, overused, or misused, including legal and illegal drugs. Urine screening is the usual method of detection.
(12 Dec 1998)
substance abuse disorders A class of mental disorders in which behavioural and biological changes are associated with regular use of alcohol, drugs, and related substances that affect the central nervous system and personal and social functioning.
(05 Mar 2000)
substance abuse, intravenous Abuse, overuse, or misuse of a substance by its injection into a vein.
(12 Dec 1998)
substance abuse treatment centres Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centres are included.
(12 Dec 1998)
substance dependence A pattern of behavioural, physiologic, and cognitive symptoms that develop due to substance use or abuse; usually indicated by tolerance to the effects of the substance and withdrawal symptoms that develop when use of the substance is terminated.
(05 Mar 2000)
substance-induced organic mental disorders Mental disorders caused by use of drugs, e.g., cocaine.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á